Aerosolized agents for airway clearance in cystic fibrosis
Kevin W Southern, John P Clancy, Sarath Ranganathan
Pediatric Pulmonology | WILEY | Published : 2019
The outlook for people with cystic fibrosis (CF) has improved considerably as a result of conventional therapies including aerosolized agents for airway clearance. These will continue to play a significant role in maintaining well-being and improving survival, even as newer agents emerge that correct the underlying CF defect. In this review, we explore the evidence supporting the use of dornase alfa, hypertonic saline, and mannitol in improving mucus clearance in patients with CF from different age groups with differing disease severity. We also discuss the clinical use of these agents in the context of available international guidelines as well as practical considerations in the clinic, hig..View full abstract
The continuing medical education webinar referred to in the manuscript was funded by an independent medical education grant from F. Hoffman-La Roche Ltd. The authors received an honorarium for the development of the content of and participating in the live webinar. The funding body had no input into the contents of the webinar and the participants had no contact with the funding body.